Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug

Bibliography

• CHAMBERS AF, MATRISIAN LM: Changing views of the role of matrix metalloproteinases in metastasis. j Natl. Cancer Inst. (1997) 89:1260–1270.
   PubMed Web of Science ®Google Scholar
• LOHI JL, WILSON CL, ROBY JD, PARKS WC: Epilysin: A novel human matrix metalloproteinase (MMP-27) expressed in testis and keratinocytes and in response to injury. j Biol. Chem. (2000) 19:19.
   Google Scholar
• PEI D: Leukolysin/MIVIP25/IVIT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res. (1999) 9:291–303.
   PubMed Web of Science ®Google Scholar
• NAGASE H: Activation mechanisms of matrix metalloproteinases. Biol. Chem. (1997) 378:151–160.
   PubMed Web of Science ®Google Scholar
• SUNDARESHAN E KOSTER JJ, NAGLE RB, BOWDEN GT: Coordinated expression of matrilysin during TPA-induced apoptosis of LNCaP cells: two parallel processes affected by TPA. Cancer Lett. (1997) 113:17–24.
   PubMed Web of Science ®Google Scholar
• WOESSNER JF, JR.: Regulation of matrilysin in the rat uterus. Biochem. Cell Biol. (1996) 74:777–784.
   PubMed Web of Science ®Google Scholar
• CURRY TE, MANN JS, ESTES RS, JONES PB: Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: collagenase inhibitors in human preovulatory ovaries. Endocrinology (1990) 127:63–68.
   PubMed Web of Science ®Google Scholar
• BREW K, DINAKARPANDIAN D, NAGASE H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta (2000) 1477:267–283.
   PubMed Web of Science ®Google Scholar
• TUMMALAPALLI CM, HEATH BJ, TYAGI SC: Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. j Cell Biochem. (2001) 80:512–521.
   PubMed Web of Science ®Google Scholar
• LI G, FRIDMAN R, KIM HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. (1999) 59:6267–6275.
   PubMed Web of Science ®Google Scholar
• LIM MS, GUEDEZ L, STETLER-STEVENSON WG, STETLER-STEVENSON M: Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann. NY Acad. Sci. (1999) 878:522–523.
   PubMed Web of Science ®Google Scholar
• GUEDEZ L, COURTEMANCH L, STETLER-STEVENSON M: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood (1998) 92:1342–1349.
   PubMed Web of Science ®Google Scholar
• BOND M, MURPHY G, BENNETT MR etal.: Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. _J. Biol. Chem. (2000) 275:41358–41363.
   Google Scholar
• SMITH MR, KUNG H, DURUM SK et al.: TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytolcirre (1997) 9:770–780.
   Google Scholar
• PATTERSON BC, SANG QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). I Biol. Chem. (1997) 272:28823–28825.
   Web of Science ®Google Scholar
• KOOP S, MACDONALD IC, LUZZI K et al.: Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res. (1995) 55:2520–2523.
   PubMed Web of Science ®Google Scholar
• KOOP S, SCHMIDT EE, MACDONALD IC etal.: Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc. Nati Acad. Li. USA (1996) 93:11080–11084.
   Google Scholar
• MORRIS VL, KOOP S, MACDONALD IC etal.: Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin. Exp. Metastasis (1994) 12:357–367.
   Google Scholar
• BRAMHALL SR: The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Mt. J. Pancreatol (1997) 21:1–12.
   Google Scholar
• KOHN EC, LIOTTA LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. (1995) 55:1856–1862.
   PubMed Web of Science ®Google Scholar
• ROSEMURGY A, HARRIS J, LANGLEBEN A etal.: Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. I Clin. Oricol. (1999) 22:247–252.
   Google Scholar
• BROWN PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opiri. Irivestig. Drugs (2000) 9:2167–2177.
   PubMed Web of Science ®Google Scholar
• SUDA T, NAGATA S: Purification and characterization of the Fas-ligand that induces apoptosis. I Exp. Med. (1994) 179:873–879.
   PubMed Web of Science ®Google Scholar
• SUDA T, TAKAHASHI T, GOLSTEIN P, NAGATA S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 75:1169–1178.
   PubMed Web of Science ®Google Scholar
• TRAUTH BC, KLAS C, PETERS AM et al.: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 245:301–305.
   PubMed Web of Science ®Google Scholar
• ITOH N, YONEHARA S, ISHII A etal.:The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 66:233–243.
   Google Scholar
• WATANABE-FUKUNAGA R, BRANNAN CI, ITOH N et al: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immurid (1992) 148:1274–1279.
   PubMed Web of Science ®Google Scholar
• CHINNAIYAN AM, O'ROURKE K, TEWARI M, DIXIT VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 81:505–512.
   PubMed Web of Science ®Google Scholar
• CHINNAIYAN AM, TEPPER CG, SELDIN MF et al: FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. j Biol. Chem. (1996) 271:4961–4965.
   PubMed Web of Science ®Google Scholar
• MUZIO M, CHINNAIYAN AM, KISCHKEL FC etal.: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death--inducing signaling complex. Cell (1996) 85:817–827.
   Google Scholar
• JUST, PANKA DJ, CUI H et al: Fas(CD95)/FasL interactions required for programmed cell death after T- cell activation. Nature (1995) 373:444–448.
   PubMed Web of Science ®Google Scholar
• STALDER T, HAHN S, ERB P: Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. Immuriol (1994) 152:1127–1133.
   Google Scholar
• LEE SH, SHIN MS, PARK WS et al: Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oricogerie (1999) 18:3754–3760.
   Google Scholar
• OWEN-SCHAUB LB, VAN GOLEN KL, HILL LL, PRICE JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp. Med. (1998) 188:1717–1723.
   PubMed Web of Science ®Google Scholar
• ABREU-MARTIN MT, VIDRICH A, LYNCH DH, TARGAN SR: Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. I Immuriol (1995) 155:4147–4154.
   Google Scholar
• BIANCONE L, MARTINO AD, ORLANDI V et al: Development of inflammatory angiogenesis by local stimulation of Fas in vivo. j Exp. Med. (1997) 186:147–152.
   PubMed Web of Science ®Google Scholar
• VON REYHER U, STRATER J, KITTSTEIN W et al.: Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. (1998) 58:526–534.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, POULAKI V, TSELENI-BALAFOUTA S et al.: Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. (2000) 60:4122–4129.
   PubMed Web of Science ®Google Scholar
• MEDEMA JP, DE JONG J, VAN HALL T etal.: Immune escape of tumors in vivo by expression of cellular FLI CE-inhibitoryprotein. J. Exp. Med. (1999) 190:1033–1038.
   Google Scholar
• BELLGRAU D, GOLD D, SELAWRY H etal.: A role for CD95 ligand in preventing graft rejection. Nature (1995) 377:630–632.
   Google Scholar
• RUNIC R, LOCKWOOD CJ, MAY et Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. I Clin. Eridocfiriol. Metab. (1996) 81:3119–3122.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, BRUNNER T, FLETCHER SM et al.: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 270:1189–1192.
   PubMed Web of Science ®Google Scholar
• HAHNE M, RIMOLDI D, SCHROTER M et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 274:1363–1366.
   PubMed Web of Science ®Google Scholar
• SAAS P, WALKER PR, HAHNE M et Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin. Invest. (1997) 99:1173–1178.
   Google Scholar
• SATO K, KIMURA E NAKAMURA Y et al.: An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br I Haematol (1996) 94:379–382.
   Google Scholar
• PERZOVA R, LOUGHRAN TP, Jr.: Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br Haematol (1997) 97:123–126.
   Google Scholar
• MULLAUER L, MOSBERGER I, CHOTT A: Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod. Pathol (1998) 11:369–375.
   PubMed Web of Science ®Google Scholar
• VILLUNGER A, EGLE A, MARSCHITZ I et al.: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood (1997) 90:12–20.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, POULAKI V, KOTOULA V etal.: Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol (1998) 153:1947–1956.
   Google Scholar
• SHIRAKI K, TSUJI N, SHIODA T et al: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA (1997) 94:6420–6425.
   PubMed Web of Science ®Google Scholar
• O'CONNELL J, O'SULLIVAN GC, COLLINS JK, SHANAHAN F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Exp. Med. (1996) 184:1075–1082.
   PubMed Web of Science ®Google Scholar
• STRAND S, HOFMANN WJ, HUG H et al.: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat. Med. (1996) 2:1361–1366.
   Web of Science ®Google Scholar
• RABINOWICH H, REICHERT TE, KASHII Y et al.: Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. I Clin. Invest. (1998) 101:2579–2588.
   Google Scholar
• GRATAS C, TOHMAY, BARNAS C et al: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. (1998) 58:2057–2062.
   PubMed Web of Science ®Google Scholar
• BENNETT MW, O'CONNELL J, O'SULLIVAN GC etal.: The Fas counterattack in vivo: apoptotic depletion of tumor- infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. ImmuriaL (1998) 160:5669–5675.
   Google Scholar
• NIEHANS GA, BRUNNER T, FRIZELLESP etal.: Human lung carcinomas express Fas ligand. Cancer Res. (1997) 57:1007–1012.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, POULAKI V, MASTORAKOS G et al.: Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J. EridocfiriaL Metab. (1999) 84:2924–2932.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, POULAKI V, LEONE A, TSOKOS M: Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J. Natl. Cancer Inst. (1999) 91:1678–1684.
   PubMed Web of Science ®Google Scholar
• TANAKA M, SUDA T, TAKAHASHI T, NAGATA S: Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. (1995) 14:1129–1135.
   PubMed Web of Science ®Google Scholar
• KAYAGAKI N, KAWASAKI A, EBATA T etal.: Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. (1995) 182:1777–1783.
   Google Scholar
• MOSS ML, JIN SL, BECHERER JD et al.:Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). j NeuraimmuriaL (1997) 72:127–129.
   PubMed Web of Science ®Google Scholar
• MOSS ML, JIN SL, MILLA ME etal.: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature (1997) 385:733–736.
   Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• TANAKA M, SUDA T, HAZE K et al.: Fas ligand in human serum. Nat. Med. (1996) 2:317–322.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, HOLLER N, BODMERJL etal.: Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp. Med. (1998) 187:1205–1213.
   Google Scholar
• TANAKA M, ITAI T, ADACHI M, NAGATA S: Downregulation of Fas ligand by shedding. Nat. Med. (1998) 4:31–36.
   PubMed Web of Science ®Google Scholar
• BRUNNER T, MOGIL RJ, LAFACE D et al.: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 373:441–444.
   PubMed Web of Science ®Google Scholar
• SHALINSKY DR, BREKKEN J, ZOU H et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Li. (1999) 878:236–270.
   PubMed Web of Science ®Google Scholar
• HEDLUND TE, DUKE RC, SCHLEICHER MS, MILLER GJ: Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate (1998) 36:92–101.
   PubMed Web of Science ®Google Scholar
• FRIESEN C, HERR I, KRAMMER PH, DEBATIN KM: Involvement of the CD95 (AP0-1/FAS) receptor/ligand system in drug- induced apoptosis in leukemia cells. Nat. Med. (1996) 2:574–577.
   PubMed Web of Science ®Google Scholar
• MULLER M, WILDER S, BANNASCH D et al.: p53 activates the CD95 (APO-1/ Fas) gene in response to DNA damage by anticancer drugs. J. Esp. Med. (1998) 188:2033–2045.
   Google Scholar
• FULDA S, SUSIN SA, KROEMER G, DEBATIN KM: Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. (1998) 58:4453–4460.
   PubMed Web of Science ®Google Scholar
• FULDA S, SCAFFIDI C, PIETSCH T et al.: Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma- irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. (1998) 5:884–893.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, KOTOULA V, TSOKOS M: FasL induction and Fas upregulation by anticancer drugs. Proc. Am. Assoc. Cancer Res. (1997) 38:194.
   Google Scholar
• MITSIADES N, YU WH, POULAKI V et al.: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. (2001) 61:577–581.
   PubMed Web of Science ®Google Scholar
• GIAVAZZI R, GAROFALO A, FERRI C et al.: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. (1998) 4:985–992.
   PubMed Web of Science ®Google Scholar
• IGARASHI N, KUBOTA T, OTANI Y et al.: Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice. Jpri. J. Cancer Res. (1999) 90:116–121.
   PubMedGoogle Scholar
• SHALINSKY DR, BREKKEN J, ZOU H et al.: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. (1999) 5:1905–1917.
   PubMed Web of Science ®Google Scholar
• POWELL WC, FINGLETON B, WILSON CL et al.: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. (1999) 9:1441–1447.
   PubMed Web of Science ®Google Scholar
• MCDONNELL S, NAVRE M, COFFEY RJ, JR., MATRISIAN LM: Expression and localization of the matrix metalloproteinase pump-1 (MIV1P- 7) in human gastric and colon carcinomas. Mal Carciriag. (1991) 4:527–533.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, ADACHI Y, ITOH F et al.: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res. (1999) 59:3313–3316.
   PubMed Web of Science ®Google Scholar
• WITTY JP, MCDONNELL S, NEWELL KJ et al.: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. (1994) 54:4805–4812.
   PubMed Web of Science ®Google Scholar
• BARILLE S, BATAILLE R, RAPP MJ et al.: Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immurial (1999) 163:5723–5728.
   Google Scholar
• KELLY T, BORSET M, ABE E et al.: Matrix metalloproteinases in multiple myeloma. Leuk. Lymphoma (2000) 37:273–281.
   PubMed Web of Science ®Google Scholar
• ZHOU H, BERNHARD EJ, FOX FE, BILLINGS PC: Induction of metalloproteinase activity in human T-lymphocytes. Biochim. Biophys Acta (1993) 1177:174–178.
   PubMed Web of Science ®Google Scholar
• GUEDEZ L, STETLER-STEVENSON WG, WOLFF L et al.: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. Clin. Invest. (1998) 102:2002–2010.
   Google Scholar